brefeldin A and Exo2 protect cells from intoxication by Shiga(-like) toxins by acting on other targets that operate at the early endosome, but do so at the cost of high toxicity to target cells. The advantage of Exo2 is that it is much more amenable to chemical modification and here we report a range of Exo2 analogues produced by modifying the tetrahydrobenzothienopyrimidine core, the vanillin moiety and the hydrazone bond that links these two. These compounds were examined for 15 the morphological changes they stimulated at the Golgi stack, the trans Golgi network and the transferrin receptor-positive early endosomes and this activity correlated with their inherent toxicity towards the protein manufacturing ability of the cell and their protective effect against toxin challenge. We have developed derivatives that can separate organelle morphology, target specificity, innate toxicity and toxin protection. Our results provide unique compounds with low 20 toxicity and enhanced specificity to unpick the complexity of membrane trafficking networks.
Introduction
Membrane and vesicular transport is fundamental to the organization and function of all eukaryotic cells. Newly 25 synthesised proteins for secretion are transported between the intracellular compartments of the endoplasmic reticulum (ER), Golgi apparatus and trans-Golgi network (TGN) using a defined set of vesicular and tubular intermediates whose formation is tightly controlled by a series of regulatory 30 proteins. A reverse pathway likewise involves the regulated formation of transport intermediates that traffic internalized proteins from the plasma membrane via the complex endosomal system and on to either lysosomes or, in the 'retrograde' pathway, the TGN, Golgi and ER.
1, 2 A cartoon 35 depicting an overview of the course of membrane transport is shown in Figure 1 . Some protein toxins highjack the retrograde route to reach the ER and deliver their lethal cargo (e.g. the bacterial cholera and Shiga-(like) toxins and plant toxin ricin) yet have been invaluable in the operate in these pathways. [3] [4] [5] [6] [7] [8] Chemical intervention with small molecule inhibitors of trafficking has also played a role but these are often pleiotropic in their action and their effects are accompanied by high levels of (often unreported) toxicity 55 (vide infra). Molecules with more specific activity and low inherent toxicity towards treated cells could finesse greater detail, understanding and control of trafficking processes.
To date, the fungal metabolite brefeldin A (BFA, Fig. 1 ) is the best characterized inhibitor of both secretion and toxin 60 retrograde transport. 9, 10 It promotes the complete disruption of the Golgi apparatus and the fusion of Golgi and ER compartments. It also significantly disrupts the structure of the TGN, promoting the tubulation and merging of the TGN and endosomal compartments. The structure of BFA and a 65 cartoon depiction of these effects are shown in the left hand lane of Figure 1 . BFA targets at least three guanine nucleotide exchange factors (GEFs) that regulate the activity of members of the ADP Ribosylation Factor (Arf) family of small GTPases. 11 These are required for the concentration of 70 cargo and the formation of coated transport carriers from various intracellular compartments such as the TGN, Golgi and early endosomes (EE). Arf1 is a critical trigger of coated carriers in the secretory and retrograde transport pathways where there are three known Arf1-specific GEFs: the Golgi-75 specific GBF1 and the TGN/endosomal BIG1 and BIG2 proteins. 12, 13 BFA inhibits all three by binding at the interface between a GDP bound Arf (GDP-Arf) and its GEF, stabilising an abortive GDP-Arf/Arf-GEF complex. 14 Several small molecule inhibitors of membrane transport have now been discovered from chemical genetics screens 7, 20-10 27 or by in silico approaches. 18 One of these molecules, 4-
is BFA-like in many respects, halting protein secretion and prompting similar morphological changes. Likewise, Exo2 15 induces complete disruption of the Golgi apparatus, fusion of Golgi and ER compartments 29 and significantly disrupts the structure of the TGN, but it does not promote the tubulation and merging of the TGN and endosomal compartments typical of treatment with BFA. 30 Thus it appears to interact with a 20 subset of the GDP-Arf/Arf-GEF targets of BFA. 30 The structure of Exo2 and a cartoon depiction of the morphological changes brought about by Exo2 treatment of cells is shown in the right hand lane of Figure 1 .
Both BFA and Exo2 exhibit a strong protective effect 25 against intoxication by the Shiga toxins, 30 , 31 major virulence factors produced by the dysentery-causing bacterium Shigella dysenteriae 32 and by enterohemorrhagic strains of E. coli, including the infamous food-poisoning serotype O157:H7. 33 These toxins normally traffic from the cell surface, via EE, 30 the TGN and the Golgi, to the ER, where the homopentameric receptor-binding B chain complex and the cytotoxic A chain are separated. The A chain then retrotranslocates the ER membrane to enter the cytosol where it inhibits protein synthesis by depurinating a specific adenosine of the 28S 35 RNA in the large ribosomal subunit. Exo2 blocks the retrograde trafficking of these toxins at the EE-TGN interface. 30 Due to its modular synthesis, 30 we were able to produce a range 34 of Exo2 analogues in an attempt to enhance these 40 attributes. The compounds were individually screened for their effect on organelle morphology and function, target specificity, innate toxicity and their ability to protect cells against an acute challenge of E. coli Shiga-like toxin I (SLTx). We have identified the functional groups that are 45 critical for the activity of Exo2 and tailored this activity to design new molecules with both enhanced target specificity and reduced inherent toxicity.
Results

Chemistry
50
Brefeldin A and Exo2 are shown in Figure 1 . To help illustrate our approach to a structure activity-relationship (SAR) study based on Exo2, we have described Exo2 in terms of rings A, B, C and E and the hydrazone linker group D (Figure 1 ). Initial studies focused on altering the fused 55 tricyclic pyrimidine core ABC involving modifications to the A ring and substitution on the pyrimidine ring C. The hydrazone link D was replaced by amine and triazole functionalities. Finally, the importance and nature of the substituents on ring E of the hydrazone was determined.
60
The intermediates made on route to generating the modifications to the tricyclic thienopyrimidone ring system are shown in Scheme 1. The thienopyrimidones 5-8, 16 were obtained using a similar synthetic route as described for Exo2. 30 Using the Gewald reaction, 35 commercial ketones 65 were condensed with ethyl cyanoacetate in the presence of sulphur to give the aminothienyl esters 1-4. Cyclisation of the esters in formamide produced the thienopyrimidones 5-8. The hydrazine derivatives 9-12 were obtained in two steps from the pyrimidones 5-8 using previously published conditions. Although these derivatives showed less inherent toxicity, they exhibited no morphological effects, had low solubility and little protective ability against STLx challenge. Concerned that the fused pyrimidine triazole ring system presented the E 90 ring of these Exo2 analogues in an inappropriate orientation (see Figure 2) , we now synthesised non-fused triazole analogues accessible via "click chemistry". 37 Our approach to these derivatives is shown in Scheme 3. Alkyne 21 was available via Sonogashira coupling between the chloride 19 95 and ethynyltrimethylsilane. Deprotection using TBAF gave the alkyne component 22. The azide partner for the formation of a "click"analogue of Exo2 was obtained in two steps from 4-nitroguaiacol 23 which was reduced to the corresponding amine 24 38 and then converted to the azide 25. 39 Benzylic azides 26-28 were synthesized from the appropriate hydroxybenzyl alcohol, 40 and the same methodology was Attention then turned to alterations on ring E where rapid access to a family of compounds to gauge the importance of the position and nature of the substituents on ring E was available from a library of hydrazone derivatives. Hydrazones 35a-r and 35w-z were prepared from condensation of 9 with 20 commercially available aldehydes (Table 3 ) and the others synthesized via a short route starting from 4-allyloxy-3- 37a-c and then deprotection gave the 3-alkyloxy-4-hydroxy substituted aldehydes 38a-c (Scheme 4). Aldehydes 38a-c were finally condensed with 9 to afford the hydrazone analogues 35s-v. The compounds shown in Table 3 probe the importance of the substituent(s) and their orientation on ring E 30 and comprise of an Exo2 isomer (35a), various hydroxy and methoxy analogues (35b to 35l ), a random selection of substituents (35m to 35r), an investigation of the meta alkoxy chain length (35s to 35v) and finally possible hydroxy isosteres (35w to 35z).
35
Biological testing.
Exo2 treatment of HeLa cells causes the fusion and swelling of the endosomes and blocks egress of SLTx from EE to the TGN. 30 We therefore probed the viability of this retrograde toxin treatment (χ, Table 1 ). Thus Exo2 has high efficacy against SLTx challenge. In contrast, the vehicle DMSO, whilst having no effect on protein synthesis ability by itself, has a small protective effect against SLTx, with ~39% protein synthesis ability remaining after toxin challenge. The small 10 protective effect of DMSO has been noted before, 43 and has been attributed to decreased fluidity of membranes which reduces toxin delivery. The morphological changes stimulated by Exo2 are believed to be responsible for its protective effect against a 15 SLTx challenge but also its inherent toxicity. 30 Thus, protection against incoming toxin might correlate with In parallel, we examined the morphological changes stimulated by these compounds. Fixed cells were stained for the TGN marker TGN46 44 and the Golgi marker giantin 45 ( Figure 1S in SI), and examined by widefield microscopy. 30 Cells treated with DMSO have a ribbon-like TGN and perinuclear Golgi, whilst in cells treated with Exo2 both of these structures are widely dispersed, leaving just a few remaining punctae. 30 An intermediate state between these morphologies is exemplified by compound 35l (see Table 3 35 and Figure Figure 1S in SI). The endosomal 'E' phenotype differs from that stimulated by BFA treatment which causes endosomal tubulation ( Figure 1S in SI) . None of the compounds tested generated a BFA phenotype at the 50 transferrin receptor (TnfR)-positive early endosomes. 
Modification of the alkylthienopyrimidine core ABC
A range of compounds were prepared varying the 10 alkylthienopyrimidine core of Exo2 and tested for their ability to inhibit SLTx transport compared with their inherent toxicity and characterised by their effects on the morphologies of the TGN/Golgi and endosomes (Table 1 and Chart S1 in SI). Increasing the cycloalkane ring size to seven (13) and 15 eight carbons (14) retains a similar protective effect (χ) ratio but shows a steep increase in toxicity with an accompanying erosion of an Exo2 phenotype. Clipping ring A, analogue 15 has less inherent toxicity but a reduced protective effect against SLTx and again showing reduced morphological 20 effects. Substitution on the pyrimidine ring (18) was similarly disadvantageous. These changes on the alkythienopyrimidine core were detrimental and highlight the importance of this structural region of Exo2 for eliciting both a protective effect and phenotypic response. This suggests that the binding site 25 cleft of the Exo2 target(s) is relatively restricted and cannot easily accommodate the larger cycloheptenyl or cyclooctenyl rings of compounds 13 and 14, but also shows a weaker interaction with the shorter core of 15.
Modifications of the hydrazone link D
30
Exchange of the hydrazone NH-N=CH fragment of Exo2 with aminoethyl NH-CH 2 -CH 2 gave compound 20 that exhibited very high toxicity drastically reducing protein synthesis ability and exhibiting no morphological effects dissuading us from further study of this group as a hydrazone replacement. 35 We have previously reported an alternative modification involving the synthesis of a series of fused 1,2,4-triazole Exo2 derivatives (see Figure 2 ) obtained by oxidative cyclisation of the precursor hydrazones.
36
These molecules unfortunately did not protect against SLTx challenge. As the ring fused 40 triazole skeletons may not present the E ring and its substituents in an optimal orientation for substrate binding, we synthesised 1,4-substituted triazoles (30) (31) (32) (33) (34) via the Huisgen 1,3-dipolar cycloaddition. 37 Although postulated as an amide isostere, 46 we considered the 1,4-substituted 1,2,3-triazole 45 could also retain the appropriate geometry and suitable atoms to chemically mimic the hydrazone bond (see Figure 2) . These triazole compounds consisted of both the analogous Exo2 derivative (30) (Table 2 ). Only the ortho or meta-hydroxyl substituted benzyl triazoles 32 and 33 exhibited a modest efficacy against SLTx challenge. We postulate that the more flexible benzyl allows presentation of the ortho or meta hydroxyl groups in a more favourable orientation to 5 compensate for the unfavourable positioning of the para hydroxy substituent of the more Exo2 like analogues 30, 31 and 34 by the 1,4-triazole linker.
Modification of the substituents on ring E
As no dramatic effects were revealed by modification of the 10 alkythienopyrimidine core and the hydrazone bond of Exo2, these moieties were used as a scaffold for a library of hydrazones examining the effect of the substituents on ring E and their orientation. The compounds, their phenotypic effects, protein synthesis and compound efficacy (χ) are 15 shown in Table 3 (Chart 3S in SI) presented in a similar manner to the previous analogues. Generally a para hydroxyl substituent confers an Exo2-like phenotype at the EE and TGN/Golgi. Comparatively, meta and ortho hydroxy substituents show a reduced Exo2 phenotypic effect (e.g. the 20 Exo2 isomer 35a and the mono substituted 35e, 35f). A meta methoxy substituent can also elicit an Exo2 phenotypic effect (35j, 35k) but with a reduced protective effect against SLTx challenge. Retention of the para OH and substitution of the meta methoxy substituent with longer alkyl ethers (35s-35v) 25 initial gives an improvement with ethoxy analogue 35s showing lower toxicity, an excellent efficacy (χ) and phenotypic effects focused at the EE. Further elongation of the ether chain quickly loses these benefits to give non-toxic inactive compounds (35u, 35v) . A similar loss of activity is 30 also noted when exchanging the meta methoxy substituent for a fluorine (35g), bromine (35h) or to the larger nitro substituent (35i). Interestingly, though having no protective effect against SLTx, 35i is able to generate an Exo2-like morphological effect at the TGN/Golgi as illustrated by the 35 redistribution of the cis-Golgi marker GRASP 65, 47 and confirmed by the dissemination of another cis-Golgi marker NA-GFP, 48 without eliciting an effect at the EE. A similar but less specific phenotypic effect is demonstrated by fluoro analogues 35n and 35o and the pyridine derivative 35p. 40 In view of the key para OH, we examined isostere replacement with an NH. This was originally disappointing as the acetamide 35w, though of low toxicity exhibited no morphological changes or protective effect against SLTx. Concerned that the additional bulk of the acetyl group of 35w 45 was inhibiting receptor binding in a similar manner to the increase in size of the meta substituent detailed above, we developed the benzimidazole derivative 35x.
This still contains the NH but the steric bulk of the meta substituent is tied back in the 5-membered ring and the nitrogens of the 50 benzimidazole 35x are ideally situated to mimic the two oxygens of the phenol and methoxy of Exo2. Pleasingly, though benzimidazole derivative 35x showed similar morphological effects to Exo2, it exhibited a lower toxicity profile and an excellent retention of protein synthesis after 55 SLTx challenge.
We promptly investigated the related indazole and indole analogues 35y and 35z. Compound 35y had reduced toxicity and an excellent protective effect. Compound 35z had protein synthesis levels approaching that of the control DMSO and retained more than 70% protein 60 synthesis after SLTx challenge with morphological effects target predominantly at the endsosomes. 
Discussion
We have generated a range of Exo2 derivatives to determine structure-activity relationships, with key alterations that define Exo2 function and alter specificity. Here we report 80 that Exo2 derivatives have differential effects on subcellular organelles, and propose that the alkylthienopyrimidine core, consisting of rings A, B and C anchors Exo2 in its target binding sites, and that the E ring is required for Exo2-like activity but also contributes towards innate toxicity. The 85 differential effects on organelles imply either that Exo2 has multiple targets, or that there is one target that exhibits varying affinities at the different sites.
At the level of light microscopy, none of the compounds tested differentiated between the Golgi and TGN, suggesting that these structures are linked intimately, with a common (set of) Exo2 target(s) which are responsible for maintaining both 5 of these structures. We were unable to make any substantially dramatic changes to Exo2 at either the E ring, the A, B and C moiety or the hydrazone link D connecting them suggesting that both ends of the molecule and their relative orientation via the hydrazone are critical for engaging with Exo2 targets. 10 A para-hydroxyl group on ring E results in dissemination of TGN/Golgi structures and swollen endosomes, and strongly inhibits the retrograde trafficking pathway of SLTx (e.g. 35b,  35d and 35g) . The protective effect of this para-hydroxyl group is context-dependent and can be eroded by increasing 15 bulk of substituents at the meta-position highlighted by increasing the meta alkoxy chain length from ethoxy to octyloxy (35s-v). Mimicry of the para-hydroxyl group by a suitably positioned -NH of a heterocyclic ring (35x-z) produces Exo2 analogues with greatly reduced toxicity, more 20 focused phenotypic effects and superior retention of protein synthesis after SLTx challenge, promising features for further investigation. There is no obvious structural relationship between Exo2 and BFA ( Figure 1) . However, the BFA cyclopentane ring carries a hydroxyl group that buries deeply 25 within the Arf:Arf-GEF BFA-binding cleft, making specific contacts with both Arf and Arf-GEF. 49 The para-hydroxyl group of Exo2 that drives Exo2 activity may therefore make similar interactions with a subset of BFA sensitive targets, underlining the importance of the hydroxyl group and 30 suggesting a possible orientation of Exo2 in such clefts. As well as modulating compound toxicity and protective effect, the nature of this substituent and its environment (meta substituent) also permit the tuning of these interactions with different targets. Clear candidates with differential specificity 35 are 35s and 35z, which preferentially target the EE and 35i which interferes at the Golgi/TGN.
The evidence that SLTx normally traffics through the Golgi stack is extensive. There are requirements for the small GTPase Arl1, 50 57, 61 have been established. Physically, subcellular microsurgery to remove the Golgi stack halts retrograde transport of the SLTx B chain to the ER. 62 However, we demonstrate here 50 that a visibly discrete Golgi structure is not an absolutely required for SLTx toxicity, since the dispersed Golgi fragments stimulated by 35i are either competent for retrograde transport or the fused ER-Golgi induced by these compounds retains functionality for retrograde transport. 55 We conclude that there are at least two Exo2 targets, one operating at the TGN/Golgi and the other operational at the TnfR+ early endosomes. Organelle morphology and function can be separated by Exo2 derivatives. The alkylthienopyrimidine ring anchors Exo2 in the target binding 60 sites, but the specificity of interaction with Exo2 targets and inherent toxicity can be altered by judicious substitution on the E ring of Exo2. Further work is now under way on the promising compounds reported here. The lower toxicity and specificity of these derivatives will allow a more rigorous 65 characterization of cell transport and the opportunity to observe recovery pathways.
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